Loading...

PATH-28. ANGIOTENSINOGEN PROMOTER METHYLATION TO PREDICT BEVACIZUMAB RESPONSE IN RECURRENT GLIOBLASTOMA PATIENTS

Recurrent glioblastoma patients achieving response to bevacizumab combination therapy have clinical improvement and prolonged survival. High gene-expression of angiotensinogen (AGT) is associated with a poor response to bevacizumab combination therapy. Because AGT gene-expression is epigenetically r...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Neuro Oncol
Main Authors: Urup, Thomas, Gillberg, Linn, Kaastrup, Katja, Schuang Lü, Maja, Regner Michaelsen, Signe, Larsen, Vibeke A, Jarle Christensen, Ib, Broholm, Helle, Lassen, Ulrik, Grønbæk, Kirsten, Skovgaard Poulsen, Hans
Format: Artigo
Sprog:Inglês
Udgivet: Oxford University Press 2019
Fag:
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC6846921/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/noz175.624
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!